ইঙ্গিত ও ব্যবহার
Fibanix is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min (or 0.075 mcg/kg/min for patients with serum creatinine ≤60 mL/min), for up to 18 hours.Pediatric Use: Safety and effectiveness in pediatric patients have not been establishedImportant Administration Instructions:To open the container, first tear off its foil overpouch. The plastic may be somewhat opaque because of moisture absorption during sterilization; the opacity will diminish gradually. Check for leaks by squeezing the inner bag firmly; if any leaks are found or sterility is suspect then the solution should be discarded. Do not use unless the solution is clear and the seal is intact. Suspend the container from its eyelet support, remove the plastic protector from the outlet port, and attach a conventional administration set.You may administer AGGRASTAT in the same intravenous line as atropine sulfate, dobutamine, dopamine, epinephrine hydrochloride (HCl), famotidine injection, furosemide, lidocaine, midazolam HCl, morphine sulfate, nitroglycerin, potassium chloride, and propranolol HCl. Do not administer AGGRASTAT through the same IV line as diazepam.Do not add other drugs or remove solution directly from the bag with a syringe.Do not use plastic containers in series connections; such use can result in air embolism by drawing air from the first container if it is empty of solution.Discard any unused portion left in the bag.
পার্শ্বপ্রতিক্রিয়া
Bleeding is the most commonly reported adverse reaction.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
General Risk of Bleeding: Bleeding is the most common complication encountered during therapy with Fibanix. Most bleeding associated with Fibanix occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, oral anticoagulants and antiplatelet drugs increases the risk of bleeding.Thrombocytopenia: Profound thrombocytopenia has been reported with Fibanix. Monitor platelet counts beginning about 6 hours after treatment initiation and daily thereafter. If the platelet count decreases to <90,000/mm3, monitor platelet counts to exclude pseudothrombocytopenia. If thrombocytopenia is confirmed, discontinue Fibanix and heparin. Previous exposure to a glycoprotein (GP) IIb/IIIa receptor antagonist may increase the risk of developing thrombocytopenia.
নিষেধাজ্ঞা
Tirofiban Hydrochloride is contraindicated in patients with: Severe hypersensitivity reaction to AGGRASTAT (i.e., anaphylactic reactions). A history of thrombocytopenia following prior exposure to AGGRASTAT. Active internal bleeding or a history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.